Search clinical trials for: Ramucirumab Paclitaxel

Total 4121 results

Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Malignant Solid Tumor

United States
Liza Villaruz, MD

Completed

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Yonsei University

Active, not recruiting

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Recurrent/Metastatic Gastric Cancer

Korea, Republic of
Yang Jianjun, PhD

Recruiting

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Advanced Gastric Cancer

China
SCRI Development Innovations, LLC
Celgene

Completed

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Gastroesophageal Cancer

United States
Eli Lilly and Company

Completed

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Adenocarcinoma

Japan
Basilea Pharmaceutica

Terminated

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)

Gastric Adenocarcinoma

Spain, United States, Korea, Republic of, Belgium, Russian Federation, United Kingdom, Italy, France, Turkey, Germany, Poland, Brazil, Australia, Argentina, Chile
Imugene Limited

Active, not recruiting

A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) (nextHERIZON)

Stomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Cancer of Stomach | Stomach Adenocarcinoma

Taiwan, Australia
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (RAINBOW)

Gastric Cancer

United States, Australia, Belgium, Korea, Republic of, Russian Federation, Germany, Poland, Spain, Argentina, Austria, Brazil, Bulgaria, Chile, Estonia, France, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Portugal, Romania, Sing... and more
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

China
Shanghai Henlius Biotech

Terminated

Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects

Healthy Male Volunteers

China
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, Taiwan, Hong Kong, Switzerland, Poland, Japan
Yonsei University

Not yet recruiting

An Open Label, Single-arm, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of T-Dxd in Combination With Ramucirumab as a 2nd Line in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction (GEJ) Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Gastric Cancer | Non-small Cell Lung Cancer | Colo-rectal Cancer

China
Seagen Inc.

Active, not recruiting

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Korea, Republic of, United Kingdom, Taiwan, Canada, Australia
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
Eli Lilly and Company
Parexel

Completed

Study of IMC-1121B in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Marina Garassino

Unknown

Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) (RELEVENT)

Thymic Carcinoma | Thymoma

Italy
Hallym University Medical Center

Not yet recruiting

Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Yale University

Withdrawn

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Transitional Cell Carcinoma

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Breast Cancer

United States
Institut für Klinische Krebsforschung IKF GmbH...
Eli Lilly and Company; Trium Analysis Online GmbH

Completed

Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy (RAMOS)

Squamous Cell Carcinoma of the Esophagus

Germany
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Healthy Participants

Healthy

United States
Athenex, Inc.

Active, not recruiting

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Gastric Cancer | Esophageal Cancer | Gastro-esophageal Cancer

Taiwan, United States
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China, Malaysia, Thailand, Philippines
Federation Francophone de Cancerologie Digestive
Eli Lilly and Company

Active, not recruiting

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE)

Stomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach Neoplasm

France
Samsung Medical Center

Recruiting

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Gastric Cancer

Korea, Republic of
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
Samsung Medical Center

Completed

Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Eli Lilly and Company

Completed

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Glioblastoma Multiforme

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, United Kingdom
ALX Oncology Inc.

Active, not recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Solid Tumor | Metastatic Cancer | Advanced Cancer | NonHodgkin Lymphoma

Korea, Republic of, United States
Eli Lilly and Company

No longer available

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Hepatocellular Carcinoma

United States
P. C. Thuss-Patience

Recruiting

Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma (AIO-STO-0218)

Gastroesophageal Junction Adenocarcinoma | Adenocarcinoma of the Stomach

Germany
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Italy, United States, Spain, Ukraine, Germany, Greece, Czechia, Turkey, Belgium, Sweden, Canada
Baylor Research Institute

Not yet recruiting

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Adenocarcinoma

United States
Hellenic Cooperative Oncology Group
Eli Lilly and Company; Celgene Corporation

Completed

RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (RACING)

Pancreatic Adenocarcinoma

Greece
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Eli Lilly and Company

Terminated

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Advanced Solid Tumor

United States, Japan
Abramson Cancer Center at Penn Medicine

Recruiting

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Non-small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company

Recruiting

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Non Small Cell Lung Cancer | Metastatic | Recurrent

United States
Eli Lilly and Company

Completed

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Breast Cancer

United States, Canada
ALX Oncology Inc.
Eli Lilly and Company

Recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Spain, France, Korea, Republic of, Taiwan, United Kingdom, Japan, Singapore, Belgium, Czechia, Italy
Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Eli Lilly and Company

Completed

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Breast Cancer

United States, Canada, Australia, Belgium, Brazil, Croatia, Czechia, Egypt, Germany, Ireland, Israel, Korea, Republic of, Lebanon, New Zealand, Peru, Poland, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, United...
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Adenocarcinoma | Gastric Cancer

United States, Canada, Brazil, Czechia, Egypt, Korea, Republic of, Lebanon, Poland, Russian Federation, Spain, Romania, United Kingdom, Australia, Croatia, Italy, Philippines, Thailand, Argentina, Bosnia and Herzegovina, Chile, ... and more
Korean South West Oncology Group

Withdrawn

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Gastric Cancer

Korea, Republic of

Search clinical trials for: Ramucirumab Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations